Tivozanib is a potent, selective and continuous inhibitor of all three vascular endothelial growth factor (VEGF) receptors that are designed to optimize VEGF blockade while minimizing off-target toxicities.
The drug, which is an oral, once-daily, investigational tyrosine kinase inhibitor, has reported positive top-line results from a Phase 3 clinical study in advanced renal cell carcinoma.
TIVO-1 is the first registration study in first-line RCC that is comparing an investigational agent against an approved VEGF therapy.
Tivozanib demonstrated superior data compared to sorafenib in the primary endpoint of progression-free survival (PFS).
Tivozanib showed a statistically significant improvement in PFS with a median PFS of 11.9 months compared to a median PFS of 9.1 months for sorafenib in the overall study population